



1-18-2016

Genomic diversity of EPEC associated with clinical presentations of differing severity

Tracy H. Hazen

University of Maryland School of Medicine, Institute for Genome Sciences, Baltimore, Maryland 21201, USA.

Michael S. Donnenberg

University of Maryland Medical Center, Baltimore, Maryland 21201, USA.

Sandra Panchalingam

University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.

Martin Antonio

Medical Research Council Unit, Atlantic Boulevard, Fajara, Banjul, Gambia

Anowar Hossain

ICDDR, B, GPO Box 128, Dhaka 1000, Bangladesh

See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr



Part of the [Gastroenterology Commons](#), [Pediatrics Commons](#), and the [Women's Health Commons](#)

Recommended Citation

Hazen, T. H., Donnenberg, M. S., Panchalingam, S., Antonio, M., Hossain, A., Mandomando, I., Ochieng, J. B., Qureshi, S., Quadri, F., Zaidi, A. (2016). Genomic diversity of EPEC associated with clinical presentations of differing severity. *Nature Microbiology*, 1, 15014.

Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/893

Authors

Tracy H. Hazen, Michael S. Donnenberg, Sandra Panchalingam, Martin Antonio, Anowar Hossain, Inacio Mandomando, John Benjamin Ochieng, Shahida Qureshi, Farheen Quadri, and Anita K. M. Zaidi



Published in final edited form as:

Nat Microbiol. ; 1: 15014. doi:10.1038/nmicrobiol.2015.14.

Genomic diversity of EPEC associated with clinical presentations of differing severity

Tracy H. Hazen^{1,2}, Michael S. Donnenberg^{3,*}, Sandra Panchalingam⁴, Martin Antonio⁵, Anowar Hossain⁶, Inacio Mandomando⁷, John Benjamin Ochieng⁸, Thandavarayan Ramamurthy⁹, Boubou Tamboura¹⁰, Shahida Qureshi¹¹, Farheen Quadri¹¹, Anita Zaidi¹¹, Karen L. Kotloff⁴, Myron M. Levine⁴, Eileen M. Barry^{2,3}, James B. Kaper², David A. Rasko^{1,2,*}, and James P. Nataro¹²

¹University of Maryland School of Medicine, Institute for Genome Sciences, 801 W. Baltimore Street, Room 600, Baltimore, Maryland 21201, USA.

²Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 West Baltimore Street, HSF-I Suite 380, Baltimore, Maryland 21201, USA.

³Department of Medicine, University of Maryland School of Medicine, University of Maryland Medical Center, N3W42, 22 S. Greene Street, Baltimore, Maryland 21201, USA.

⁴Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, Maryland 21201, USA.

⁵Medical Research Council Unit, Atlantic Boulevard, Fajara, P.O. Box 273, Banjul, Gambia.

⁶ICDDR, B, GPO Box 128, Dhaka 1000, Bangladesh.

⁷Centro de Investigacao em Saude, Manhica, Rua 12, Cambeve, Vila de Manhiça, CP 1929, Maputo, Mozambique.

⁸Kenya Medical Research Institute/CDC, P.O. Box 54840 – 00200, Kisumu, Kenya.

⁹National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road, Scheme XM, Belegghata, Kolkata 700 010, India.

¹⁰Center for Vaccine Development – Mali, Bamako, Mali.

¹¹The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Pakistan.

Reprints and permissions information is available online at www.nature.com/reprints.

*Correspondence and requests for materials should be addressed to M.S.D. and D.A.R. mddonnenb@umaryland.edu; drasko@som.umaryland.edu.

Author contributions

T.H.H., M.S.D., J.P.N. and D.A.R. conceived and designed the experiments. T.H.H., M.S.D., E.M.B., J.B.K., J.P.N. and D.A.R. performed the experiments. T.H.H., M.S.D., E.M.B., J.B.K., J.P.N. and D.A.R. analysed the data. S.P., M.A., A.H., I.M., J.B.O., T.R., B.T., S.Q., F.Q., A.Z., K.L.K., M.M.L. and J.P.N. contributed materials from the GEMS studies. T.H.H., M.S.D., E.M.B., J.B.K., J.P.N. and D.A.R. co-wrote the paper.

Additional information

Supplementary information is available online.

Competing interests

The authors declare no competing financial interests.

Accession numbers. The genome sequence assemblies generated in this study were deposited in GenBank under the accession numbers listed in Table 1.

¹²Department of Pediatrics, University of Virginia School of Medicine, P.O. Box 800386, Charlottesville, Virginia 22908, USA.

Abstract

Enteropathogenic *Escherichia coli* (EPEC) are diarrhoeagenic *E. coli*, and are a significant cause of gastrointestinal illness among young children in developing countries. Typical EPEC are identified by the presence of the bundle-forming pilus encoded by a virulence plasmid, which has been linked to an increased severity of illness, while atypical EPEC lack this feature. Comparative genomics of 70 total EPEC from lethal (LI), non-lethal symptomatic (NSI) or asymptomatic (AI) cases of diarrhoeal illness in children enrolled in the Global Enteric Multicenter Study was used to investigate the genomic differences in EPEC isolates obtained from individuals with various clinical outcomes. A comparison of the genomes of isolates from different clinical outcomes identified genes that were significantly more prevalent in EPEC isolates of symptomatic and lethal outcomes than in EPEC isolates of asymptomatic outcomes. These EPEC isolates exhibited previously unappreciated phylogenomic diversity and combinations of virulence factors. These comparative results highlight the diversity of the pathogen, as well as the complexity of the EPEC virulence factor repertoire.

Enteropathogenic *E. coli* (EPEC) are a cause of moderate to severe diarrhoea in young children, primarily in developing countries¹. The Global Enteric Multicenter Study (GEMS), an epidemiological study of children with moderate to severe diarrhoea and children with no diarrhoea, has demonstrated that EPEC is a leading cause of lethality associated with diarrhoea among children that are less than 12 months of age^{2,3}. By definition, EPEC contain the locus of enterocyte effacement (LEE) pathogenicity island, which encodes a type III secretion system (T3SS) involved in the pathogenesis of these organisms⁴⁻⁷. The LEE region is a defining feature of the attaching and effacing *E. coli* (AEEC), which includes EPEC and the Shiga toxin-producing enterohaemorrhagic *E. coli* (EHEC), which are associated with severe food-related illness worldwide⁸⁻¹¹. EPEC are further categorized by the presence or lack of the plasmid-encoded bundle-forming pilus genes (BFP)^{8,12}, which are commonly found on the EPEC adherence factor (EAF) plasmid and confer localized adherence (LA) to the surface of intestinal epithelial cells¹³⁻¹⁶. The BFP operon is frequently identified in EPEC associated with diarrhoeal illness, and these isolates are termed typical EPEC (tEPEC)^{8,17}. *E. coli* that possess the LEE region, but do not contain the BFP or Shiga toxin genes (LEE+/stx-/bfp-), are commonly termed atypical EPEC (aEPEC)¹⁷. Previous studies investigating the genetic diversity of aEPEC have demonstrated that LEE+/stx-/bfp- isolates are a diverse group that can include among them isolates that are more related to other *E. coli* pathovars and commensal isolates^{18,19}. The aEPEC can also include EHEC and EPEC that have lost the Shiga-toxin genes and BFP genes during passage through a host or the environment or after culture in the laboratory^{18,19}.

Investigation of the genetic and virulence factor diversity of tEPEC has focused mainly on isolates within two lineages, EPEC1 and EPEC2²⁰, as defined by multi-locus sequence typing (MLST)²⁰. MLST and phylogenetic analysis have also described additional tEPEC lineages, EPEC3 and EPEC4²⁰, as well as EPEC5 and EPEC6, which comprise aEPEC isolates¹⁹, suggesting that there is probably greater genetic diversity among EPEC isolates

than originally anticipated. Until the recent comparative genomic analysis of a collection of diverse AEEC isolates¹⁸, which included additional EPEC1, EPEC2 and the first EPEC4 genomes described, the genome sequences available for EPEC isolates were limited to E2348/69, B171, E22 (a rabbit EPEC isolate) and E110019 (an aEPEC isolate)^{21,22}. Even with recent sequencing, the majority of the EPEC genomes sequenced are historical isolates from developed countries, and little is known regarding the genomic diversity of recent EPEC isolates from developing countries, where EPEC has been identified in the recent landmark GEMS analysis as an important pathogen of children, with tEPEC associated with the greatest amount of mortality².

In the present study we sequenced the genomes and performed comparative genomic analysis of 70 EPEC isolates from children less than 5 years of age enrolled in GEMS². Phylogenomic analysis of these 70 EPEC isolates highlighted the considerable evolutionary diversity and variability of EPEC virulence mechanisms in more recent EPEC isolates from developing countries. By comparing the genomes of 24 EPEC from lethal cases (LI), 23 EPEC from non-lethal symptomatic cases (NSI) and 23 EPEC from asymptomatic cases (AI), we identified the genes that are more frequently associated with EPEC from different clinical outcomes. Genomic studies such as this provide valuable insight into the diversity and virulence mechanisms of an *E. coli* pathogen that is associated with increased risk of death among infants in developing countries³. The findings of this study can be used to generate improved methods for molecular diagnostics of EPEC that will provide information regarding the evolutionary history of an isolate as previously described¹⁸. The genes that were identified as more frequently associated with lethal or symptomatic EPEC isolate genomes may be further characterized to obtain a deeper understanding of the EPEC pathogenesis and provide additional targets for vaccine and therapeutic development.

Results

Phylogenomic analysis of GEMS site EPEC isolates associated with different clinical outcomes

To investigate the genomic diversity and virulence mechanisms of EPEC isolated from individuals with differing clinical severity we sequenced the genomes of 70 EPEC from multiple geographic sites included in GEMS³. The 70 EPEC isolates were obtained from cases of diarrhoeal illness in children classified as LI or NSI, or as controls with asymptomatic (AI) outcomes. There were a total of 24 EPEC isolates from LI cases, 23 from NSI cases and 23 from AI cases. The 24 EPEC isolates from LI cases were all tEPEC, and 20 of 23 (87%) of the EPEC from NSI cases and 17 of 23 (74%) of the EPEC from AI cases were tEPEC.

Phylogenomic analysis of the 70 EPEC isolate genomes, together with a collection of previously sequenced AEEC isolates and diverse *E. coli* and *Shigella*¹⁸, demonstrated that there is greater genomic diversity among recent EPEC isolates from Africa and Asia than in prototype *E. coli* isolates^{2,3,23} (Fig. 1). The 70 EPEC isolates were present in *E. coli* phylogroups A, E, B1 and B2^{18,24}, demonstrating considerable genomic diversity for *E. coli* belonging to a single pathovar (Fig. 1 and Tables 1 and 2). The majority of the isolates were in phylogroups B2 (55.7%, 39/70) and B1 (34.3%, 24/70), each of which included multiple

E. coli isolates from various pathovars, as well as laboratory-adapted and commensal *E. coli* (Fig. 1 and Table 2). Overall, the phylogenomic lineages were not geographically confined, with the exception of the isolates belonging to EPEC lineages in phylogroup A (EPEC5, EPEC10), which were restricted to only two sites (The Gambia and Kenya) (Fig. 1 and Table 2).

An MLST-based phylogeny was also constructed using anchor isolates of the previously described EPEC lineages, EPEC1–EPEC6^{19,20}. This allowed the identification of relationships among the 70 EPEC isolates sequenced in the current study to the previous MLST-defined EPEC lineages (Fig. 1 and Supplementary Fig. 1). Remarkably, only 16 (22.9%) of the isolates sequenced were present in the two main previously identified MLST-based lineages of EPEC, EPEC1 and EPEC2, with eight in each lineage (Fig. 1 and Tables 1 and 2). An additional eight genomes (11.4%) were in the EPEC4 lineage (Fig. 1 and Tables 1–2), which has previously been described by MLST and a single genome has been sequenced^{18,20}. Another three genomes of isolates 103338, 401140 and 401210 grouped in the MLST-based phylogeny with an isolate previously designated as EPEC5 using MLST²⁰ (Supplementary Fig. 1). The remaining 43 genomes formed novel EPEC phylogenomic lineages. This finding indicates that there is considerable uncharacterized EPEC genomic diversity identified in this study (Fig. 1). To extend the established MLST-based nomenclature, we are designating four previously undescribed phylogenomic lineages, which each contain five or more genomes, EPEC7–10 (Fig. 1 and Supplementary Table 1). Eleven of these genomes were in the EPEC7 phylogenomic lineage and B1 phylogroup (Table 2). In phylogroup B2 there were ten genomes forming the EPEC8 phylogenomic lineage and six in the EPEC9 phylogenomic lineage (Fig. 1 and Table 2). The remaining two genomes belong to the EPEC10 lineage, which was designated when combined with three previously sequenced LEE+/*stx*–/*bfp*–isolates¹⁸ (Fig. 1 and Table 2). The four newly described EPEC lineages contain 41.4% (29/70) of the isolates, highlighting the undescribed diversity of global EPEC isolates.

In addition to these novel lineages, there were 14 genomes not assigned to phylogenomic lineages EPEC1–10, which thus represent unclassified EPEC isolates. These isolates were distributed throughout the *E. coli* phylogeny (Fig. 1 and Table 1). Of these 14 unclassified EPEC isolates, only one was associated with an LI case, two with NSI cases and 11 with AI controls (Fig. 1 and Table 2), and six of these isolates were *bfpA*– (Fig. 1). Thus, the unclassified EPEC isolates comprised nearly half (11/23, 48%) of the AI isolates, whereas the LI and NSI isolates were primarily associated with phylogenomic lineages that contained one or more tEPEC. These distributions suggest there may be an optimal EPEC genomic content that is required for the greatest virulence.

Distribution of EPEC virulence-associated genes

The expanded genome phylogeny described here identified a previously unrecognized phylogenetic distribution of EPEC isolates; however, it was unclear whether these differences extended to the known EPEC virulence factors. In addition to the T3SS encoded by the LEE pathogenicity island^{5,25}, present in all genomes sequenced in this study, there were additional virulence-associated secretion systems detected in the isolates sequenced in

this study (Supplementary Table 1). Among these regions was a type II secretion system (T2SS) and a type VI secretion system (T6SS), both of which exhibited phylogroup- and lineage-specific distributions (Supplementary Table 1). Investigation of the sequence diversity of previously characterized T3SS effectors demonstrated that the effectors exhibited greater similarity by phylogenomic lineage than by clinical outcome (Supplementary Fig. 2).

Phylogenetic analysis of the *bfpA* nucleotide sequences present in each of the 61 *bfpA*+ genomes sequenced in this study, with 11 reference *bfpA* alleles^{20,26} and 31 *bfpA* alleles from previously sequenced EPEC genomes¹⁸, demonstrated that the majority of the *bfpA* genes belonged to one of three main phylogenetic groups as defined by Blank and colleagues²⁶ (Supplementary Fig. 3a). Each of the phylogenetic groups of *bfpA* contains isolates from diverse phylogenomic lineages and clinical outcomes (LI, NSI and AI). This is in contrast to the intimin gene, *eae*, from the LEE pathogenicity region, which exhibits greater phylogenomic lineage specificity (Supplementary Fig. 3b). This difference suggests that *bfpA*, and by extension the entire *bfp* operon and possibly the entire EAF plasmid, have been lost and acquired multiple times by *E. coli* isolates belonging to diverse EPEC phylogenomic lineages.

Interestingly, all of the LI isolates analysed in this study were found to be *bfpA*+ by PCR, as previously described¹⁸, with the exception of isolate 100414, which was *bfpA*- (Table 1 and Supplementary Table 1). However, on detailed examination of the genome sequence, EPEC isolate 100414 was determined to encode a *bfpA* orthologue with 72% nucleotide identity to *bfpA* of the E2348/69 EAF plasmid, pMAR2²². The 100414 *bfpA* allele exhibited greater phylogenetic similarity to a *bfpA*-like sequence from the LEE-negative EAEC isolate 101-1²¹ (Supplementary Fig. 3a).

Identification of EPEC genes associated with different clinical outcomes

To identify whether there are genes that are more prevalent among the 70 EPEC from different clinical presentations, we used large-scale BLAST score ratio (LS-BSR) analysis^{27,28} to analyse the whole genome content. The LS-BSR analysis places predicted homologous genes from each genome into gene clusters that have $\geq 90\%$ nucleotide identity²⁹. For the 70 genomes analysed in this study, 12,964 gene clusters were identified and 1,080 gene clusters were present in all 70 genomes analysed (LS-BSR ≥ 0.9). These gene clusters represent the conserved EPEC core genome. This is a more conservative approach than was previously used to define the *E. coli* species core genome and so the absolute number of genes is smaller than the *E. coli* core genome defined previously^{21,30}.

A comparison of gene cluster prevalence in LI genomes versus AI genomes demonstrated a significant correlation ($P < 0.05$) of 367 gene clusters (Table 3 and Supplementary Table 2). Among the gene clusters represented in a greater number of LI than AI genomes were genes of the EAF plasmid, flagellin, an allele of the T3SS effector NleG, as well as many hypothetical and phage-associated genes (Supplementary Table 2). There were 111 clusters that were significantly more prevalent in LI genomes or in NSI genomes (Table 3). Among the genes that were more prevalent among the LI genomes were many that encoded hypothetical proteins, putative transcriptional regulators, a putative T3SS effector EspJ and

putative phage-associated genes (Supplementary Table 2). Similarly, there were 118 gene clusters that were statistically more prevalent in NSI genomes versus AI genomes (Table 3).

Although we identified gene clusters with a significant correlation with one symptomatic group compared to another symptomatic group (Table 4 and Supplementary Table 3), there were no gene clusters that were detected in all of the LI genomes that were absent from all of the NSI and AI genomes. The absence of universal clinically associated genes may partly be a result of the vast genomic diversity of the isolates associated with each of the clinical outcomes (Fig. 1 and Supplementary Table 3). However, there were 428 gene clusters that were statistically ($P < 0.05$) more prevalent among the symptomatic (LI and NSI) compared to asymptomatic (AI) genomes, and 40 of these gene clusters had a P value of < 0.005 (Table 4 and Supplementary Table 4). These gene clusters that were more prevalent among symptomatic compared to asymptomatic group genomes included numerous hypothetical proteins and phage and plasmid-associated genes (Supplementary Table 4). When the distribution of these 428 gene clusters was compared by hierarchical cluster analysis, the EPEC isolates formed three main groups that included all of the genomes, except three isolates that were outliers (Fig. 2). Group I contained nine of the ten EPEC8 isolates and the only EPEC8 isolate that was not within group I was part of group III and associated with an asymptomatic outcome (Fig. 2). Thus, all of the EPEC isolates of group I were associated with symptomatic outcomes (five LI and four NSI). Meanwhile, group II contained 18 isolates, all belonging to *E. coli* phylogroup B2. Seven of these isolates (39%) were associated with symptomatic outcomes, while the other 11 (61%) EPEC isolates were from asymptomatic outcomes (Fig. 2). The largest group was group III, which contained 40 isolates, including 31 (78%) from symptomatic outcomes and nine (22%) from asymptomatic outcomes (Fig. 2). The EPEC isolate genomes of group III primarily belonged to phylogroups B1 and A, with the exception of four EPEC9 isolates and seven EPEC4 isolates from phylogroup B2 (Fig. 2).

To investigate whether there were similar trends observed when comparing only the tEPEC isolates, we excluded the nine aEPEC isolates. Comparison of the tEPEC from the three different clinical outcomes (LI versus NSI, LI versus AI and NSI versus AI) identified fewer gene clusters that were significantly ($P < 0.05$) associated with one clinical outcome over another than were identified when comparing all 70 EPEC genomes (see Table 3 and Supplementary Table 3 for a clinical presentation and Table 4 and Supplementary Table 5 for symptomatic versus asymptomatic comparisons). These findings suggest there is an increased genomic diversity associated with the aEPEC isolates.

Hierarchical cluster analysis of the presence of the 258 gene clusters significantly associated with only tEPEC of symptomatic or asymptomatic outcomes separated the tEPEC isolates into two similarly sized groups (Supplementary Fig. 4). tEPEC group I contained 34 isolates, including 20 (59%) from symptomatic (LI or NSI) outcomes and 14 (41%) from asymptomatic outcomes (Supplementary Fig. 4). Meanwhile, tEPEC group II contained 27 genomes; 24 (89%) from symptomatic outcomes and only three (11%) from asymptomatic outcomes (Supplementary Fig. 4). Within each of these tEPEC groups the isolates were present in subgroups based on phylogenomic lineage. There were 20 gene clusters that were present in all of the genomes of tEPEC group I that were absent from all genomes of tEPEC

group II (Supplementary Fig. 4 and Supplementary Table 5) including gene products predicted to be involved in propanediol utilization (Supplementary Table 5), which has been implicated in *Salmonella* for its role during survival in the host^{31,32}.

EPEC-specific genes associated with different clinical outcomes

To identify genes that were associated with EPEC isolates of different clinical outcomes, while taking into account the considerable underlying genomic diversity of these isolates, we performed LS-BSR analysis using a decreased clustering threshold of 80% nucleotide identity to combine potential alleles. Commensal genomes were included (*E. coli* HS (NC_009800.1), K-12 (NC_000913.3) and SE11 (NC_011415.1)) in the analysis as a metric for counter selection. This approach provided the opportunity to identify genetic features that were present only in the EPEC, regardless of phylogenomic lineage. For this analysis there were 12,196 total gene clusters. Of those, there were 6,474 gene clusters (53%) that were present in one or more of the EPEC genomes that were absent (LS-BSR < 0.8) from all of the commensal isolates. Using this EPEC-only data set and examining all 70 EPEC isolate genomes, the number of gene clusters that were significantly ($P < 0.05$) associated with one clinical outcome over another ranged from 39 to 198 (Table 3 and Supplementary Table 6). Similarly, when comparing only the 61 tEPEC genomes, the number of genes associated with genomes of one clinical outcome over another was lower, ranging from 7 to 134 (Table 3 and Supplementary Table 7). Furthermore, the number of genes significantly associated with symptomatic (LI and NSI) compared to asymptomatic (AI), or lethal (LI) compared to non-lethal (NSI and AI) genomes was decreased (Table 4 and Supplementary Table 8). The number of gene clusters associated with symptomatic or asymptomatic genomes was 246 when comparing all 70 EPEC isolates (Table 4, Supplementary Table 8 and Supplementary Fig. 5) and 141 when comparing only the 61 tEPEC isolates (Table 4, Supplementary Table 9 and Supplementary Fig. 6).

Many of the gene clusters that were associated with one clinical outcome were annotated as hypothetical proteins (Supplementary Table 4). To examine the potential function of the predicted peptides, the gene clusters were examined for protein domains identified in membrane-associated or secreted proteins, which would suggest they might be directly involved in surface expression or survival. Of the 39 to 246 gene clusters that were identified as significantly associated with one clinical outcome in the analysis of all 70 EPEC (Tables 3 and 4), the number of gene clusters with protein domains of secreted or surface-associated proteins ranged from 11 to 50 (Supplementary Table 10). Similarly, of the 7 to 141 gene clusters significantly associated with one clinical outcome in the analysis of only the tEPEC genomes (Tables 3 and 4), the number of gene clusters containing membrane-associated or secreted protein domains was low, ranging from 2 to 31 (Supplementary Table 10). Among the gene clusters that were significantly more prevalent in symptomatic compared to asymptomatic genomes were hypothetical proteins, a putative *yfdA*, an acetyltransferase, a putative pyridoxamine 5-phosphate-dependent dehydrase, a glycosyl transferase family protein, and plasmid conjugal transfer-associated proteins (Supplementary Tables 8 and 9). These analyses provide targets for the functional characterization of these gene products in pathogenesis.

Discussion

The whole-genome sequencing and phylogenomic analysis of 70 EPEC isolates from children enrolled in GEMS^{2,3} demonstrated that *E. coli* clinical isolates identified as EPEC based only on their virulence factor content exhibit considerable genomic diversity. Phylogenomic analysis demonstrated that 61% (43/70) of the EPEC isolates examined occupy previously undescribed phylogenomic lineages. This study may have identified newly circulating EPEC in the GEMS sites, but may also highlight the dynamic evolutionary processes that are at work in *E. coli* pathogens. Of note, a recent study on EPEC demonstrated a shift in the epidemiology from tEPEC to aEPEC isolates¹, but this study focused on the tEPEC isolates associated with an adverse outcome. The current study is not meant to be a comprehensive genomic view of all the tEPEC collected with GEMS, but a focused attempt to identify genetic factors associated with the isolates from the most severe outcomes.

The EPEC genome comparisons demonstrated that the degree of genomic difference was greater when comparing the extremes of the clinical presentation, LI to AI genomes, than it was when comparing LI to NSI, or NSI to AI (Table 2). This emphasizes the finding from the phylogenomic analysis that isolates associated with a particular clinical outcome can occur in distantly related EPEC phylogenomic lineages (Fig. 1). Thus, the smaller number of genomic differences identified between the lethal and non-lethal EPEC isolates suggests the differences in the illness severity caused by these isolates may have less to do with the bacterium and more to do with host factors including, but not limited to, co-morbidities, the micro-biome, diet, breast-feeding and access to medical care, among other factors. Overall, these findings suggest that there is not a single gene or genomic region that is responsible for particular EPEC isolates causing more severe clinical outcomes, but it may instead require a collection of genomic regions acting in concert, as well as responding to host factors that will result in more severe infection by EPEC. The gene clusters that are more prevalent in the genomes of EPEC from different clinical outcomes provide a genomic view of what potentially makes certain EPEC isolates more virulent. Among these were many genes with unknown functions, including some that contain predicted protein domains of membrane-associated or secreted proteins that can be investigated for their contribution to the virulence mechanism of EPEC and potentially other pathogenic *E. coli*. A recent study by Hazen *et al.*³³ describes the comparative transcriptome analysis of four prototype EPEC isolates: E2348/69 (EPEC1), B171 (EPEC2), C581-05 (EPEC4) and E110019 (prototype aEPEC isolate)³³. That study identified that there is also transcriptional variation among these prototype isolates³³. Further investigation is required to examine the transcriptional variation among the new EPEC lineages described in the current study. The combination of genomics and transcriptomics will provide further insight into the conserved and expressed EPEC features involved in virulence.

Large-scale comparative genomic studies that assess the diversity of disease-causing bacteria associated with multiple types of clinical outcome, such as this, provide a framework for understanding the processes that underlie the evolution of pathogenesis. This study describes a number of phylogroup- and lineage-specific differences in the virulence factor and genome content, which suggests that EPEC isolates have continued to acquire genetic changes since

their initial acquisition of some of the pathovar-defining features. These studies can also provide insight into the ongoing evolution of the virulence mechanisms of disease-causing bacteria. The emergence of diarrhoea-causing EPEC and the severity of illness attributed to these isolates depend on a suite of genes that includes both lineage-specific virulence factors and genes encoded by plasmid and phage. These regions will provide fertile ground for the examination of EPEC pathogenesis and the development of a possible vaccine against EPEC in the future.

Methods

Bacterial isolates

The bacterial isolates analysed in this study, and the details of each of the genomes sequenced, are listed in Table 1 and also described in a companion study³⁴. The EPEC (LEE +/*bfpA*+/*stx*-) isolates analysed in this study were obtained from GEMS as previously described^{2,23}. A total of 24 tEPEC isolates from lethal cases (LI) were obtained, representing all tEPEC isolates associated with a lethal outcome in GEMS^{2,23}. The isolates from lethal outcomes were from only five sites of the seven in GEMS (The Gambia, Mal, Mozambique, Kenya and Pakistan), so there is an over-representation of isolates from Africa. A matching scheme using geography and clinical parameters of the subject was used to select one EPEC isolate from a non-lethal symptomatic case (NSI) and one EPEC isolate from an asymptomatic case (AI) representing controls for each tEPEC from a lethal case as previously described³⁴. One NSI case and one AI case served as controls for two different LI cases, resulting in 23 EPEC from NSI cases and 23 EPEC from AI cases. A tEPEC isolate (*bfpA*+) was obtained from 20 of the NSI cases and 17 of the AI cases, with the remaining EPEC cases containing an aEPEC (*bfpA*-). The recent publication by Donnenberg *et al.*³⁴ describes the case-control aspect of this study and the comparison of the isolates that were directly matched based on patient and clinical parameters. In the current study we delve into the phylogenomic content of the isolates, irrespective of matching criteria and only consider the genotypic presentation of EPEC and the outcome of the infection.

Genome sequencing and assembly

Genomic DNA was isolated from each strain by growing a single colony that was PCR-positive for the LEE-encoded gene *escV* and/or the EAF plasmid gene *bfpA*, overnight, in Luria-Bertani (LB) medium at 37 °C with shaking. The genomic DNA was isolated from the overnight culture using the GenElute Genomic kit (Sigma-Aldrich), then sequenced and assembled as previously described^{18,34}.

Phylogenomic analysis

The 70 EPEC genomes sequenced in this study were compared with 37 previously sequenced *E. coli* and *Shigella* genomes by whole-genome phylogenomic analysis as previously described^{18,35}.

Gene alignments and phylogenetic analyses

The individual gene phylogenies of *eae* and *bfpA* were generated as described previously¹⁸. The nucleotide sequences were aligned in MEGA5³⁶ using the ClustalW algorithm³⁷. A

maximum-likelihood phylogeny was then constructed using the Kimura two-parameter model of distance estimation³⁸ with 1,000 bootstrap replications.

A phylogenetic analysis of seven conserved housekeeping genes that have been used for MLST was generated for the isolates characterized in this study compared to a collection of previously sequenced EPEC and other *E. coli* isolates as previously described^{18,20}. The EPEC1-4 reference sequences types (STs) included in the phylogeny are those identified by Lacher *et al.*²⁰ while the EPEC5 and EPEC6 reference sequences were described by Tennant and co-workers.¹⁹

BSR analysis

The presence or absence of known virulence-associated genes in the genome sequences generated in this study was determined using BLAST score ratio (BSR) analysis, as described previously^{18,27,28}. The protein-encoding genes that were considered present with significant similarity had BSR values of ≥ 0.8 , while those with BSR values < 0.8 but ≥ 0.4 were considered to be present but divergent.

The level of similarity of protein-encoding genes was compared across genomes in this study using a large-scale BLAST score ratio (LS-BSR) analysis as previously described^{18,28,29}. The gene clusters were assigned using a stringent nucleotide identity threshold of $\geq 90\%$ (Data Set S1), or using a more inclusive nucleotide identity threshold of $\geq 80\%$ (Data Set S2). The LS-BSR analysis performed using the more inclusive clustering threshold of $\geq 80\%$ included the 70 genomes in this study and three commensal genomes: *E. coli* HS (NC_009800.1), K-12 (NC_000913.3) and SE11 (NC_011415.1). The predicted protein function of each gene cluster was determined using an ergatis-based³⁹ in-house annotation pipeline⁴⁰.

Hierarchical cluster analysis⁴¹ of the LS-BSR gene clusters associated with particular clinical outcomes was performed using Pearson correlation with average linkage using MeV⁴². The gene clusters compared were considered either present (blue) with an LS-BSR of ≥ 0.9 (with 90% clustering threshold) or ≥ 0.8 (with 80% clustering threshold) or absent (white) when < 0.9 or < 0.8 .

Statistical analysis

Statistical significance of the prevalence of predicted gene clusters among genomes associated with different symptomatic groups was determined using the Pearson's chi-square test with Yates' continuity correction when the number of genomes was five or more, or the Fisher's exact test when the number of genomes in one or both groups being compared was less than five, calculated using R v. 3.1.1⁴³. *P* values of < 0.05 were considered statistically significant.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This project was funded by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services NIH grant no. U19 AI090873.

References

1. Ochoa TJ, Contreras CA. Enteropathogenic *Escherichia coli* infection in children. *Curr. Opin. Infect. Dis.* 2011; 24:478–483. [PubMed: 21857511]
2. Kotloff KL, et al. The global enteric multicenter study (GEMS) of diarrheal disease in infants and young children in developing countries: epidemiologic and clinical methods of the case/control study. *Clin. Infect. Dis.* 2012; 55(Suppl 4):S232–S245. [PubMed: 23169936]
3. Kotloff KL, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. *Lancet.* 2013; 382:209–222. [PubMed: 23680352]
4. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. *Proc. Natl Acad. Sci. USA.* 1995; 92:1664–1668. [PubMed: 7878036]
5. Elliott SJ, et al. The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic *Escherichia coli* E2348/69. *Mol. Microbiol.* 1998; 28:1–4. [PubMed: 9593291]
6. Perna NT, et al. Molecular evolution of a pathogenicity island from enterohemorrhagic *Escherichia coli* O157:H7. *Infect. Immun.* 1998; 66:3810–3817. [PubMed: 9673266]
7. Tauschek M, Strugnell RA, Robins-Browne RM. Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic *Escherichia coli*. *Mol. Microbiol.* 2002; 44:1533–1550. [PubMed: 12067342]
8. Kaper JB, Nataro JP, Mobley HL. Pathogenic *Escherichia coli*. *Nature Rev. Microbiol.* 2004; 2:123–140. [PubMed: 15040260]
9. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet.* 2005; 365:1073–1086. [PubMed: 15781103]
10. Clements A, Young JC, Constantinou N, Frankel G. Infection strategies of enteric pathogenic *Escherichia coli*. *Gut Microbes.* 2012; 3:71–87. [PubMed: 22555463]
11. Pennington H. *Escherichia coli* O157. *Lancet.* 2010; 376:1428–1435. [PubMed: 20971366]
12. Nataro JP, Scaletsky IC, Kaper JB, Levine MM, Trabulsi LR. Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic *Escherichia coli*. *Infect. Immun.* 1985; 48:378–383. [PubMed: 2859247]
13. Bieber D, et al. Type IV pili, transient bacterial aggregates, and virulence of enteropathogenic *Escherichia coli*. *Science.* 1998; 280:2114–2118. [PubMed: 9641917]
14. Donnenberg MS, Giron JA, Nataro JP, Kaper JB. A plasmid-encoded type IV fimbrial gene of enteropathogenic *Escherichia coli* associated with localized adherence. *Mol. Microbiol.* 1992; 6:3427–3437. [PubMed: 1362446]
15. Stone KD, Zhang HZ, Carlson LK, Donnenberg MS. A cluster of fourteen genes from enteropathogenic *Escherichia coli* is sufficient for the biogenesis of a type IV pilus. *Mol. Microbiol.* 1996; 20:325–337. [PubMed: 8733231]
16. Donnenberg MS, Zhang HZ, Stone KD. Biogenesis of the bundle-forming pilus of enteropathogenic *Escherichia coli*: reconstitution of fimbriae in recombinant *E. coli* and role of DsbA in pilin stability—a review. *Gene.* 1997; 192:33–38. [PubMed: 9224871]
17. Nataro JP, Kaper JB. Diarrheagenic *Escherichia coli*. *Clin. Microbiol. Rev.* 1998; 11:142–201. [PubMed: 9457432]
18. Hazen TH, et al. Refining the pathovar paradigm via phylogenomics of the attaching and effacing *Escherichia coli*. *Proc. Natl Acad. Sci. USA.* 2013; 110:12810–12815. [PubMed: 23858472]
19. Tennant SM, et al. Characterisation of atypical enteropathogenic *E. coli* strains of clinical origin. *BMC Microbiol.* 2009; 9:117. [PubMed: 19490652]

20. Lacher DW, Steinsland H, Blank TE, Donnenberg MS, Whittam TS. Molecular evolution of typical enteropathogenic *Escherichia coli*: clonal analysis by multilocus sequence typing and virulence gene allelic profiling. *J. Bacteriol.* 2007; 189:342–350. [PubMed: 17098897]
21. Rasko DA, et al. The pangenome structure of *Escherichia coli*: comparative genomic analysis of *E. coli* commensal and pathogenic isolates. *J. Bacteriol.* 2008; 190:6881–6893. [PubMed: 18676672]
22. Iguchi A, et al. Complete genome sequence and comparative genome analysis of enteropathogenic *Escherichia coli* O127:H6 strain E2348/69. *J. Bacteriol.* 2009; 191:347–354. [PubMed: 18952797]
23. Panchalingam S, et al. Diagnostic microbiologic methods in the GEMS-1 case/control study. *Clin. Infect. Dis.* 2012; 55(Suppl 4):S294–S302. [PubMed: 23169941]
24. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal *Escherichia coli*. *Nature Rev. Microbiol.* 2010; 8:207–217. [PubMed: 20157339]
25. Deng W, et al. Dissecting virulence: systematic and functional analyses of a pathogenicity island. *Proc. Natl Acad. Sci. USA.* 2004; 101:3597–3602. [PubMed: 14988506]
26. Blank TE, Zhong H, Bell AL, Whittam TS, Donnenberg MS. Molecular variation among type IV pilin (bfpA) genes from diverse enteropathogenic *Escherichia coli* strains. *Infect. Immun.* 2000; 68:7028–7038. [PubMed: 11083828]
27. Rasko DA, Myers GS, Ravel J. Visualization of comparative genomic analyses by BLAST score ratio. *BMC Bioinf.* 2005; 6:2.
28. Sahl JW, Caporaso JG, Rasko DA, Keim P. The large-scale blast score ratio (LS-BSR) pipeline: a method to rapidly compare genetic content between bacterial genomes. *PeerJ.* 2014; 2:e332. [PubMed: 24749011]
29. Sahl JW, et al. Evolution of a pathogen: a comparative genomics analysis identifies a genetic pathway to pathogenesis in *Acinetobacter*. *PLoS ONE.* 2013; 8:e54287. [PubMed: 23365658]
30. Touchon M, et al. Organised genome dynamics in the *Escherichia coli* species results in highly diverse adaptive paths. *PLoS Genet.* 2009; 5:e1000344. [PubMed: 19165319]
31. Conner CP, Heithoff DM, Julio SM, Sinsheimer RL, Mahan MJ. Differential patterns of acquired virulence genes distinguish *Salmonella* strains. *Proc. Natl Acad. Sci. USA.* 1998; 95:4641–4645. [PubMed: 9539791]
32. Heithoff DM, et al. Coordinate intracellular expression of *Salmonella* genes induced during infection. *J. Bacteriol.* 1999; 181:799–807. [PubMed: 9922242]
33. Hazen TH, et al. RNA-Seq analysis of isolate- and growth phase-specific differences in the global transcriptomes of enteropathogenic *Escherichia coli* prototype isolates. *Front. Microbiol.* 2015; 6:569. [PubMed: 26124752]
34. Donnenberg MS, et al. Bacterial factors associated with lethal outcome of enteropathogenic *Escherichia coli* infection: genomic case-control studies. *PLoS Negl. Trop. Dis.* 2015; 9:e0003791. [PubMed: 25978422]
35. Sahl JW, et al. A comparative genomic analysis of diverse clonal types of enterotoxigenic *Escherichia coli* reveals pathovar-specific conservation. *Infect. Immun.* 2011; 79:950–960. [PubMed: 21078854]
36. Tamura K, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* 2011; 28:2731–2739. [PubMed: 21546353]
37. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* 1994; 22:4673–4680. [PubMed: 7984417]
38. Kimura M. A simple method for estimating evolutionary rate of base substitutions through comparative studies of nucleotide sequences. *J. Mol. Evol.* 1980; 16:111–120. [PubMed: 7463489]
39. Orvis J, et al. Ergatis: a web interface and scalable software system for bioinformatics workflows. *Bioinformatics.* 2010; 26:1488–1492. [PubMed: 20413634]
40. Galens K, et al. The IGS standard operating procedure for automated prokaryotic annotation. *Stand. Genomic Sci.* 2011; 4:244–251. [PubMed: 21677861]
41. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. *Proc. Natl Acad. Sci. USA.* 1998; 95:14863–14868. [PubMed: 9843981]

42. Saeed AI, et al. TM4 microarray software suite. *Methods Enzymol.* 2006; 411:134–193. [PubMed: 16939790]
43. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2010.
44. Angiuoli SV, Salzberg SL. Mugsy: fast multiple alignment of closely related whole genomes. *Bioinformatics.* 2011; 27:334–342. [PubMed: 21148543]
45. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics.* 2006; 22:2688–2690. [PubMed: 16928733]




Figure 1. Phylogenomic analysis of the 70 EPEC isolates associated with clinical outcomes of differing severity compared with select previously sequenced AEEC genomes and a reference collection of 25 diverse *E. coli* and *Shigella* isolate genomes

The whole-genome assemblies were aligned using Mugsy⁴⁴ as previously described¹⁸. The regions of sequence that aligned in all genomes were concatenated into a single 820,355-bp sequence for each genome, and the concatenated sequences were used to generate a maximum-likelihood phylogeny with 100 bootstrap replications, which was constructed using RAxML v.7.2.8⁴⁵, and visualized using FigTree v.1.4.2 (<http://tree.bio.ed.ac.uk/software/figtree/>). Bootstrap values of ≥ 80 are designated on the tree by a filled circle. Genomes examined in this study that were obtained from lethal cases (LI) are indicated in orange, those from non-lethal symptomatic (NSI) cases are indicated in green and isolates from asymptomatic (AI) cases in blue. The presence of *bfpA* is indicated by a star symbol. The four novel EPEC phylogenomic lineages identified in this study are indicated by an asterisk.




Figure 2. Identification of genes associated with symptomatic and asymptomatic EPEC isolates

The plot is a hierarchical cluster analysis of the 428 LS-BSR gene clusters that were significantly (chi-square test or Fisher's exact test, $P < 0.05$) more prevalent in genomes of symptomatic (LI and NSI) compared to asymptomatic (AI) cases for all 70 EPEC genomes analysed. The LS-BSR gene clusters, generated using a clustering threshold of 90% nucleotide identity, that were significantly (chi-square test or Fisher's exact test $P < 0.05$) associated with genomes of symptomatic compared to asymptomatic cases, were compared by hierarchical clustering⁴¹. Hierarchical clustering with Pearson correlation and average linkage was performed using MeV⁴². Each column represents a genome, and each row is an LS-BSR gene cluster. The gene clusters that were present with an LS-BSR value of ≥ 0.9 are indicated in blue, and the gene clusters that were absent (LS-BSR value of < 0.9) in white.

Red boxes indicate three groups of genomes, designated I, II and III, and red asterisks identify the nodes that separate the genomes into the three groups. The colour-coded rectangles at the top of the plot denote the phylogenomic lineage, and the colour-coded squares indicate the clinical outcome of each isolate. The colour coding of each symbol is given in the key at the top of the figure. A star symbol denotes the presence of *bfpA* in each genome.

Table 1

Genome characteristics of the isolates sequenced in this study.

Specimen ID	Clinical outcome*	Location	BFP [†]	Intimin type [‡]	MLST ST (clonal group)	Phylogenomic lineage [§]	Phylogroup [§]	Draft genome size (Mb)	No. of contigs	Accession no.
100290	LI	The Gambia	+	alpha	236 (6)	EPEC1	B2	5.42	115	JHQV000000000
100343	LI	The Gambia	+	beta	140 (31)	EPEC7	B1	5.07	154	JHQW000000000
100414	LI	The Gambia	+	beta2	ND	EPEC4	B2	5.31	116	JHQX000000000
102550	LI	The Gambia	+	epsilon	555 (NA)	NC	B1	5.17	209	JHQY000000000
103385	LI	The Gambia	+	mu	ND	EPEC8	B2	5.05	149	JHQZ000000000
103573	LI	The Gambia	+	beta	140 (31)	EPEC7	B1	5.15	134	JHRA000000000
203741	LI	Mali	+	beta2	23 (7)	EPEC4	B2	5.05	446	JHRE000000000
300059	LI	Mozambique	+	mu	ND	EPEC8	B2	4.83	122	JHRC000000000
300262	LI	Mozambique	+	mu	ND	EPEC8	B2	4.97	111	JHRD000000000
302014	LI	Mozambique	+	beta	118 (17)	EPEC2	B2	5.23	527	JHRE000000000
302048	LI	Mozambique	+	alpha	ND	EPEC1	B2	5.27	436	JHRF000000000
302053	LI	Mozambique	+	lambda	ND	EPEC9	B2	4.94	420	JHRG000000000
302275	LI	Mozambique	+	mu	ND	EPEC8	B2	5.01	394	JHRH000000000
302662	LI	Mozambique	+	beta	140 (31)	EPEC7	B1	5.13	478	JHRI000000000
303289	LI	Mozambique	+	alpha	ND	EPEC1	B2	5.09	144	JHRJ000000000
400791	LI	Kenya	+	beta	140 (31)	EPEC7	B1	5.32	170	JHRK000000000
401031	LI	Kenya	+	alpha [‡]	18 (6)	EPEC1	B2	5.04	170	JHRL000000000
401140	LI	Kenya	+	epsilon	433 (23)	EPEC5	A	5.00	255	JHRM000000000
401150	LI	Kenya	+	beta	140 (31)	EPEC7	B1	5.08	142	JHRN000000000
401264	LI	Kenya	+	mu	ND	EPEC8	B2	5.14	228	JHRO000000000
401954	LI	Kenya	+	beta	118 (17)	EPEC2	B1	5.32	287	JHRP000000000
402290	LI	Kenya	+	beta	140 (31)	EPEC7	B1	5.36	109	JHRQ000000000
702324	LI	Pakistan	+	alpha	228 (5)	EPEC9	B2	5.01	96	JHRR000000000
703533	LI	Pakistan	+	beta	ND	EPEC2	B1	5.30	549	JHRS000000000
100329	NSI	The Gambia	+	ND [‡]	169 (23)	EPEC10	A	4.81	390	JHRT000000000
100854	NSI	The Gambia	-	theta	171 (23)	EPEC10	A	4.69	101	JHRU000000000
102536	NSI	The Gambia	+	beta2	23 (7)	EPEC4	B2	5.30	134	JHRV000000000

Specimen ID	Clinical outcome*	Location	BFP [†]	Intimin type [‡]	MLST ST (clonal group)	Phylogenomic lineage [§]	Phylogroup [§]	Draft genome size (Mb)	No. of contigs	Accession no.
102598	NSI	The Gambia	+	alpha	236 (6)	EPEC1	B2	5.36	187	JHRW000000000
102929	NSI	The Gambia	-	zeta	535 (28)	NC	B1	5.24	147	JHRX000000000
103578	NSI	The Gambia	+	beta [‡]	118 (17)	EPEC2	B1	5.11	376	JHRY000000000
200146	NSI	Mali	+	beta	140 (31)	EPEC7	B1	5.13	125	JHRZ000000000
300075	NSI	Mozambique	+	lambda	ND	EPEC9	B2	4.97	103	JHSA000000000
300214	NSI	Mozambique	+	mu	ND	EPEC8	B2	5.07	104	JHSB000000000
300231	NSI	Mozambique	+	beta2	23 (7)	EPEC4	B2	5.13	79	JHSC000000000
302150	NSI	Mozambique	+	beta2	ND	EPEC4	B2	4.94	286	JHSD000000000
302687	NSI	Mozambique	+	beta [‡]	140 (31)	EPEC7	B1	5.00	394	JHSE000000000
302909	NSI	Mozambique	+	lambda	ND	NC	B2	4.79	254	JHSF000000000
303145	NSI	Mozambique	+	lambda	ND	EPEC9	B2	4.84	102	JHSG000000000
400738	NSI	Kenya	+	beta2	23 (7)	EPEC4	B2	5.16	102	JHSH000000000
401091	NSI	Kenya	+	beta	140 (31)	EPEC7	B1	5.09	89	JHSI000000000
401210	NSI	Kenya	-	epsilon [‡]	433 (23)	EPEC5	A	4.57	781	JHSJ000000000
401588	NSI	Kenya	+	mu	ND	EPEC8	B2	5.10	100	JHSK000000000
401817	NSI	Kenya	+	mu	ND	EPEC8	B2	4.90	96	JHSL000000000
402310	NSI	Kenya	+	mu	ND	EPEC8	B2	5.11	94	JHSM000000000
402804	NSI	Kenya	+	beta	118 (17)	EPEC2	B1	5.48	135	JHSN000000000
702423	NSI	Pakistan	+	beta	140 (31)	EPEC2	B1	5.40	181	JHSO000000000
702626	NSI	Pakistan	+	beta	140 (31)	EPEC2	B1	5.23	237	JHSP000000000
100100	AI	The Gambia	-	gamma	78 (12)	NC	E	5.27	123	JHSQ000000000
100175	AI	The Gambia	-	epsilon2	254 (43)	NC	B1	4.85	89	JHSR000000000
102132	AI	The Gambia	-	gamma	78 (12)	NC	E	5.28	110	JHSS000000000
102535	AI	The Gambia	+	mu	ND	EPEC8	B2	4.79	97	JHST000000000
103338	AI	The Gambia	T	kappa	933 (NA)	EPEC5	A	4.66	112	JHSU000000000
103447	AI	The Gambia	+	epsilon	555 (NA)	NC	B1	5.09	182	JHSV000000000
200077	AI	Mali	+	eta	20 (NA)	NC	B2	5.09	141	JHSW000000000
300469	AI	Mozambique	+	alpha	228 (5)	EPEC9	B2	4.51	64	JHSX000000000
300847	AI	Mozambique	+	lambda	ND	EPEC9	B2	4.85	385	JHSY000000000
302137	AI	Mozambique	-	zeta	378 (7)	EPEC4	B2	5.10	44	JHSZ000000000

Specimen ID	Clinical outcome*	Location	BFP [†]	Intimin type [‡]	MLST ST (clonal group)	Phylogenomic lineage [§]	Phylogroup [§]	Draft genome size (Mb)	No. of contigs	Accession no.
302312	AI	Mozambique	+	alpha	ND	NC	B2	5.15	115	JHTA000000000
303139	AI	Mozambique	+	epsilon	555 (NA)	NC	B1	4.93	150	JHTB000000000
303301	AI	Mozambique	+	alpha	ND	NC	B2	4.91	100	JHTC000000000
303341	AI	Mozambique	-	beta	140 (31)	EPEC7	B1	5.06	86	JHTD000000000
400929	AI	Kenya	+	alpha	236 (6)	EPEC1	B2	5.04	139	JHTE000000000
401195	AI	Kenya	+	alpha [‡]	18 (6)	EPEC1	B2	4.89	194	JHTF000000000
401675	AI	Kenya	+	lambda	ND	NC	B2	4.95	125	JHTG000000000
402559	AI	Kenya	+	kappa	8 (3)	NC	B2	4.99	288	JHTH000000000
402981	AI	Kenya	+	beta2	23 (7)	EPEC4	B2	5.17	75	JHTI000000000
403116	AI	Kenya	+	alpha	ND	EPEC1	B2	4.97	108	JHTJ000000000
403341	AI	Kenya	-	beta	140 (31)	EPEC7	B1	5.17	111	JHTK000000000
700283	AI	Pakistan	+	kappa	562 (NA)	NC	B2	4.76	97	JHTL000000000
703450	AI	Pakistan	+	beta	ND	EPEC2	B1	5.52	289	JHTM000000000

ND, not determined; NC, not classified

* the clinical outcomes are LI (lethal), NSI (non-lethal symptomatic) and AI (asymptomatic)

[†] a '+' indicates that one or more genes of the BFP operon are present, '-' indicates an isolate that has a truncated *bfp* operon and 'T' indicates that no BFP genes were detected

[‡] the intimin types of these isolates are truncated and these are the most related intimin types

[§] the phylogenomic lineage and phylogroup designations are based on the genome-based phylogeny in Fig. 1.

Table 2

Distribution of the 70 EPEC isolates from different clinical outcomes analysed in this study.

Phylogroup or lineage	* Total isolates (% of total)	BFP [†]	Clinical outcomes (% of phylogroup or lineage) [‡]			Location (% of phylogroup or lineage)					
			LI	NSI	AI	The Gambia	Mali	Mozambique	Kenya	Pakistan	
Total isolates	70	61 (87.1)	24 (34.2)	23 (32.9)	23 (32.9)	18 (25.7)	3 (4.3)	22 (31.4)	21 (30)	6 (8.6)	
Phylogroup B2	39 (55.7)	38 (62.3)	13 (33.3)	12 (30.8)	14 (35.9)	6 (15.4)	2 (5.1)	17 (43.6)	12 (30.8)	2 (5.1)	
EPEC1	8 (11.4)	8 (100)	4 (50)	1 (12.5)	3 (37.5)	2 (25)	0 (0)	2 (25)	4 (50)	0 (0)	
EPEC4	8 (11.4)	7 (87.5)	2 (25)	4 (50)	2 (25)	2 (25)	1 (12.5)	3 (37.5)	2 (25)	0 (0)	
EPEC8	10 (14.3)	10 (100)	5 (50)	4 (40)	1 (10)	2 (20)	0 (0)	4 (40)	4 (40)	0 (0)	
EPEC9	6 (8.6)	6 (100)	2 (33.3)	2 (33.3)	2 (33.3)	0 (0)	0 (0)	5 (83.3)	0 (0)	1 (16.7)	
uAEEC	7 (10)	7 (100)	0 (0)	1 (14.3)	6 (85.7)	0 (0)	1 (14.3)	3 (42.8)	2 (28.6)	1 (14.3)	
Phylogroup B1	24 (34.3)	20 (32.8)	10 (41.7)	8 (33.3)	6 (25)	7 (29.2)	1 (4.2)	5 (20.8)	7 (29.2)	4 (16.6)	
EPEC2	8 (11.4)	8 (100)	3 (37.5)	4 (50)	1 (12.5)	1 (12.5)	0 (0)	1 (12.5)	2 (25)	4 (50)	
EPEC7	11 (15.7)	9 (81.8)	6 (54.5)	3 (27.3)	2 (18.2)	2 (18.2)	1 (9.1)	3 (27.3)	5 (45.4)	0 (0)	
uAEEC	5 (7.1)	3 (60)	1 (20)	1 (20)	3 (60)	4 (80)	0 (0)	1 (20)	0 (0)	0 (0)	
Phylogroup A	5 (7.1)	3 (4.9)	1 (20)	3 (60)	1 (20)	3 (60)	0 (0)	0 (0)	2 (40)	0 (0)	
EPEC5	3 (4.3)	2 (66.7)	1 (33.3)	1 (33.3)	1 (33.3)	1 (33.3)	0 (0)	0 (0)	2 (66.7)	0 (0)	
EPEC10	2 (2.9)	1 (50)	0 (0)	2 (100)	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	
Phylogroup E	2 (2.9)	0 (0)	0 (0)	0 (0)	2 (100)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	
uAEEC	2 (2.9)	0 (0)	0 (0)	0 (0)	2 (100)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	
Phylogroups B1, B2, E	14 (20)	10 (71.4)	1 (7.1)	2 (14.3)	11 (78.6)	6 (42.9)	1 (7.1)	4 (28.6)	2 (14.3)	1 (7.1)	

* The phylogenomic lineages are determined based on the genome phylogeny, and uAEEC indicates an 'uncharacterized' AEEC that is not in a known lineage

[†] includes isolates that have a truncated BFP operon; the percentages are calculated for each lineage

[‡] the clinical outcomes are lethal (LI), non-lethal symptomatic (NSI) and asymptomatic (AI).

Table 3

Number of gene clusters identified using LS-BSR that are significantly correlated with one clinical outcome when compared to another clinical outcome.

Clinical outcomes [*]	No. of genomes	No. of gene clusters			
		Lineage-specific [†] LS-BSR ≥ 0.9		EPEC-specific [‡] LS-BSR ≥ 0.8	
		<0.005	<0.05	<0.005	<0.05
All genomes					
LI vs AI					
Total	47	20	367	12	198
LI	24	19	227	11	134
AI	23	1	140	1	64
LI vs NSI					
Total	47	1	111	0	39
LI	24	0	31	0	14
NSI	23	1	80	0	25
NSI vs AI					
Total	46	7	118	4	67
NSI	23	5	63	1	27
AI	23	2	55	3	40
Typical EPEC genomes only					
LI vs AI					
Total	41	11	238	2	134
LI	24	11	167	2	96
AI	17	0	71	0	38
LI vs NSI					
Total	44	0	39	0	7
LI	24	0	9	0	5
NSI	20	0	30	0	2
NSI vs AI					
Total	37	7	176	0	87
NSI	20	4	89	0	24
AI	17	3	87	0	63

* Clinical outcomes are classified as lethal (LI), non-lethal symptomatic (NSI) and asymptomatic (AI)

[†] as part of a lineage-specific gene comparison, genes with $\geq 90\%$ nucleotide identity were grouped together into gene clusters, and the gene clusters were identified as more prevalent in genomes of one clinical outcome over another by the percentage of genomes of each group that contained the gene cluster with significant similarity (LS-BSR ≥ 0.9)

[‡] as part of an EPEC pathovar-specific comparison, genes with $\geq 80\%$ nucleotide similarity were grouped together into gene clusters and the gene clusters were identified as more prevalent in genomes of one clinical outcome over another by the percentage of genomes of each group that contained the gene cluster with significant similarity (LS-BSR ≥ 0.8) that were not present in three previously characterized *E. coli* commensal genomes (K-12, SE11, HS).

Table 4

Number of gene clusters identified using LS-BSR that are significantly correlated with genomes of a particular clinical outcome.

Clinical outcomes [*]	No. of genomes	No. of gene clusters			
		Lineage-specific [†] LS-BSR ≥ 0.9		EPEC-specific [‡] LS-BSR ≥ 0.8	
		<0.005	<0.05	<0.005	<0.05
All genomes					
Symptomatic vs asymptomatic					
Total	70	40	428	24	246
LI+NSI	47	25	258	12	109
AI	23	15	170	12	137
Lethal vs non-lethal					
Total	70	38	308	7	135
LI	24	12	170	7	122
NSI+AI	46	26	138	0	13
Typical EPEC genomes only					
Symptomatic vs asymptomatic					
Total	61	31	258	15	141
LI+NSI	44	8	151	3	58
AI	17	23	107	12	83
Lethal vs non-lethal					
Total	61	11	202	2	86
LI	24	5	103	2	71
NSI+AI	37	6	99	0	15

^{*}The symptomatic clinical outcomes are classified as lethal (LI) and non-lethal symptomatic (NSI) and non-lethal are the NSI and asymptomatic (AI)

[†]genes with $\geq 90\%$ nucleotide identity were grouped together into gene clusters, and the gene clusters were identified as more prevalent in genomes of one clinical outcome over another by the percentage of genomes of each group that contained the gene cluster with significant similarity (LS-BSR ≥ 0.9)

[‡]genes with $\geq 80\%$ nucleotide similarity were grouped together into gene clusters, and the gene clusters were identified as more prevalent in genomes of one clinical outcome over another by the percentage of genomes of each group that contained the gene cluster with significant similarity (LS-BSR ≥ 0.8) that were not present in three previously characterized *E. coli* commensal genomes (K-12, SE11, HS).